NDA 202207 · Cardinal Health 414
Lymphoseek Kit
Technetium Tc-99m Tilmanocept · Injection
NovelOrphanLast checked: Nov 20, 2026Latest source record: May 19, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Mar 13, 2013
Approved uses
4
Original approval plus efficacy supplements
Registered trials
29
4 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2026.
Lymphoseek is a radioactive diagnostic agent indicated with or without scintigraphic imaging for: • Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management. • Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma. Lymphoseek is a radioactive diagnostic agent indicated with or without scintigraphic imaging for: • Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management. ( 1 ) • Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma. ( 1 )
Mechanism: Lymphoseek (technetium Tc 99m tilmanocept) is a radioactive diagnostic agent. It accumulates in lymphatic tissue and selectively binds to mannose binding receptors (CD206) located on the surface of macrophages and dendritic cells. Technetium Tc 99m tilmanocept is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone. The mannose acts as a ligand for the receptor, and the DTPA serves as a chelating agent for labeling with technetium Tc 99m.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 19, 2021 Supplement 12 · Efficacy OrphanLetterLabel
- Oct 14, 2014 Supplement 2 · Efficacy LabelLetter
- Jun 13, 2014 Supplement 1 · Efficacy · priority review LetterLabel
- Mar 13, 2013 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLetterLabel
1 products under this application
- LYMPHOSEEK KIT · TECHNETIUM TC-99M TILMANOCEPT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Tilmanocept" as an intervention, any sponsor and status, largest first.
- Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and MelanomaPivotal-lookingCompleted
Navidea BiopharmaceuticalsIndustry
NCT00671918 · 186 participants · Start Apr 2008 · Primary completion Jun 2009
Drug: Lymphoseek · For: Breast Cancer; Melanoma
Sites: Alexander City, Alabama; Birmingham, Alabama; La Jolla, California · 15 sites in all
- Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RAPivotal-lookingTerminated
Navidea BiopharmaceuticalsIndustry
NCT05246280 · 169 participants · Start Mar 2, 2022 · Primary completion Jul 9, 2024
Drug: TC99m-tilmanocept · For: Rheumatoid Arthritis
Sites: Beverly Hills, California; San Francisco, California; Avon Park, Florida · 13 sites in all
- Breast and Melanoma Trial With Lymphoseek to Identify Lymph NodesPivotal-lookingCompleted
Navidea BiopharmaceuticalsIndustry
NCT01106040 · 163 participants · Start Jun 2010 · Primary completion Apr 2011
Drug: Lymphoseek · For: Breast Cancer; Melanoma
Sites: Birmingham, Alabama; La Jolla, California; San Francisco, California · 8 sites in all
- Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m TilmanoceptCompleted
Navidea BiopharmaceuticalsIndustry
NCT04947137 · 134 participants · Start May 27, 2021 · Primary completion Jan 21, 2022
Drug: Tc99m tilmanocept · For: Rheumatoid Arthritis
Sites: Miami Lakes, Florida; Palmetto Bay, Florida; Kettering, Ohio · 7 sites in all
Navidea BiopharmaceuticalsIndustry
NCT03938636 · 116 participants · Start Apr 8, 2019 · Primary completion Feb 8, 2021
Drug: Tc 99m tilmanocept · For: Rheumatoid Arthritis
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 10 sites in all
- Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell CarcinomaPivotal-lookingTerminated
Navidea BiopharmaceuticalsIndustry
NCT00911326 · 101 participants · Start May 2009 · Primary completion Aug 2013
Drug: Lymphoseek · For: Head and Neck Squamous Cell Carcinoma (HNSCC)
Sites: Birminham, Alabama; La Jolla, California; San Diego, California · 13 sites in all
Memorial Health University Medical CenterAcademic, hospital or other
NCT03199560 · 86 participants (planned) · Start Jun 22, 2017 · Primary completion Jun 22, 2019
Drug: Tc 99m tilmanocept; Tc 99m filtered sulfur colloid · For: Sentinel Lymph Node Biopsy; Breast Cancer
Sites: Savannah, Georgia
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT07121595 · 50 participants (planned) · Start Jul 17, 2025 · Primary completion Jul 1, 2030
Drug: Carboplatin; Cisplatin and 1 more · For: Oral Cavity Squamous Cell Carcinoma; Stage I Lip and Oral Cavity Cancer AJCC v8; Stage II Lip and Oral Cavity Cancer AJCC v8 and 2 more
Sites: Ann Arbor, Michigan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Cardinal Health 414
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.